New Study Reveals Long-Term Risks of Platinum Chemotherapy in Children
By Editor • September 10, 2026 • 1 min read
Recent research has unveiled concerning findings regarding the use of platinum-based chemotherapy, specifically cisplatin and carboplatin, in treating childhood cancers. While these drugs have significantly improved survival rates for conditions like hepatoblastoma, a common liver cancer in children, they may also carry hidden dangers that could affect patients in the long run.
Historically, children diagnosed with hepatoblastoma faced a grim prognosis, with just a 20% chance of surviving five years. Thanks to the introduction of platinum-based treatments, that figure has soared to over 80% for localized cases. Despite these advancements, the study published in Science raises alarms about the potential genetic mutations caused by these treatments.
Focusing on the children treated with these chemotherapy agents, the research aims to shed light on the mutations that occur not just in cancerous cells, but also in healthy ones. While similar mutations have been observed in adults, their long-term implications in pediatric patients remain under-explored, prompting the need for ongoing monitoring and further investigation.
Source: www.statnews.com
#chemotherapy #children's health #DNA mutations #hepatoblastoma #platinum drugs
